semaglutide vision A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no GLP-1 drugs and vision loss:

Together, the findings shed light on how to turn down the "volume" on food noise, whether through pharmacology, mental training, or a combination of both

Others tolerate faster escalation

This represents a key limitation of our study, as there may be variations in clinical outcomes and tolerance across the dose spectrum that our analysis could not detect

[1] This modest increase is generally not considered clinically significant for most patients and does not usually require treatment modification

Our medical team provides guidance, monitoring, and ongoing support at every stage of treatment

Tirzepatide typically produces greater weight loss in clinical trials than semaglutide, with patients losing 20-22% body weight versus 15-17% respectively